CSIMarket
 
Acorda Therapeutics Inc   (ACOR)
Other Ticker:  
 
 
Price: $12.4000 $-0.55 -4.210%
Day's High: $14.11 Week Perf: 3.33 %
Day's Low: $ 12.40 30 Day Perf: -20.51 %
Volume (M): 3 52 Wk High: $ 18.21
Volume (M$): $ 36 52 Wk Avg: $10.73
Open: $14.11 52 Wk Low: $0.45



 Market Capitalization (Millions $) 15
 Shares Outstanding (Millions) 1
 Employees 327
 Revenues (TTM) (Millions $) 111
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Acorda Therapeutics Inc
Acorda Therapeutics Inc is a biopharmaceutical company based in Ardsley, New York, that specializes in the development and commercialization of therapies for neurological disorders.
The company primarily focuses on developing therapies for patients with Parkinson's disease, multiple sclerosis, and spinal cord injuries.
Acordaes primary business is the development and commercialization of Ampyra (dalfampridine), which is approved in the United States for the improvement of walking in people with multiple sclerosis.
This drug works by blocking potassium channels, which leads to an increase in nerve impulse transmission, ultimately improving walking ability in MS patients.
Apart from Ampyra, Acorda has a rich pipeline of products that it is developing for the treatment of neurological disorders.
The companyes pipeline includes products for the treatment of Parkinsones disease, as well as other products for spinal cord injuries and epilepsy.
The company also conducts product research and development activities in partnership with leading academic institutions and biotechnology companies.
Acorda has a strong research-focused culture, and the company invests a significant amount of its revenues in R&D.
The company has a dedicated team of professionals, including scientists, researchers, and medical specialists, who work tirelessly to bring new products to market.
Overall, Acorda Therapeutics Inc is a well-respected and innovative biopharmaceutical company that is dedicated to the development of therapies for neurological disorders.
The company's focus on research and development, as well as its strong pipeline of products, makes it one of the leading biopharmaceutical companies in the neuroscience sector.


   Company Address: 2 Blue Hill Plaza Pearl River 10965 NY
   Company Phone Number: 347-4300   Stock Exchange / Ticker: NASDAQ ACOR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Acorda Therapeutics Inc

Acorda Therapeutics Inc Defies Market Odds with Surging Share Performance Despite Growing Deficit

Acorda Therapeutics Inc Reports Swelling Deficit but Positive Share Performance Inspires Investors
October 15, 2023
Acorda Therapeutics Inc, a renowned biopharmaceutical company, has recently released its financial report for the interval ending on September 30, 2023. Despite a significant increase in the company's deficit, Acorda Therapeutics' shares have shown impressive improvement over the past three months, indicating a positive outlook for investors.
According to the report, the company's deficit has swelled to $-7.16 per share compared to $-0.57 per share in the same period the previous year. However, in a positive turn of events, the company's income per share has improved from $-7.55 to -$7.16 per share from the preceding reporting season.

Acorda Therapeutics Inc

Acorda Therapeutics Inc Overcomes Challenges with Stellar Year-to-Date Performance, but Second Quarter Revenue Decline Poses Hurdle

Over the course of the last five trading days, Acorda Therapeutics Inc stock experienced a 1.89% increase, leading to a year-to-date performance of an impressive 1854.78%. Additionally, the stock has reached its 52-week high. However, despite these positive developments, the company faced some challenges in its second quarter of 2023 earnings season.
One of the key issues was lower revenue, which resulted in losses for Acorda Therapeutics Inc. Revenue fell by -4.431% to $29.68 million in the second quarter, compared to the same quarter in the previous year. This decline in revenue contributed to a shortfall per share of $-7.55, compared to a shortfall of $-2.78 per share in the corresponding quarter a year ago.

Acorda Therapeutics Inc

Acorda Therapeutics Inc. Decreases Losses by 62% in Q1 2023, Boosting Investor Confidence2. Acorda Therapeutics Inc. displays impressive financial progress in Q1 2023, reporting reduced losses and improved revenue

Investors in Acorda Therapeutics Inc. may be pleased to hear that the company's losses have decreased significantly in the first quarter of 2023, as compared to the same period a year ago. The company reported a loss of $-0.69 per share, compared to $-1.85 a year prior. Similarly, the EPS fell from $0.51 per share from the preceding reporting period.
While the company's revenue decreased by -1.225% to $22.26 million from $22.53 million in the corresponding reporting period a year prior, and sequentially revenue fell by -29.272% from $31.47 million, the net shortfall of $-16.824 million was significantly less than the deficit of $-24.522 million in the corresponding reporting period a year ago.






 

Acorda Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com